09-Oct-2026
Intelligence Overview
The U.S. Food and Drug Administration (USFDA) has issued the guidance document “Postapproval Manufacturing Changes to Biosimilar and Interchangeable Biosimilar Products: Questions and Answers” in October 2026.
Developed by the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER), the guidance provides recommendations for reporting and supporting manufacturing changes made to licensed biosimilar and interchangeable biosimilar products.
Key Highlights
- Manufacturing Change Reporting: Explains the information applicants should provide when reporting postapproval manufacturing changes.
- Reporting Categories: Addresses the appropriate reporting categories for manufacturing changes, including Prior Approval Supplements (PAS), changes being reported through supplements, and annual reports, as applicable.
- Product Quality Assessment: Emphasizes evaluating the potential impact of manufacturing changes on product identity, strength, quality, purity, and potency.
- Comparability Considerations: Aligns recommendations with the principles of ICH Q5E on comparability of biotechnological and biological products following manufacturing process changes.
- Regulatory Compliance: Supports applicants in understanding FDA expectations for maintaining the quality, safety, and effectiveness of licensed biosimilar products throughout their lifecycle.
Regulatory Significance
The guidance provides a practical reference for regulatory affairs, quality assurance, and CMC professionals involved in biosimilar lifecycle management. Understanding the appropriate reporting category and supporting data requirements can help companies assess manufacturing changes and prepare suitable regulatory submissions.
Source: https://www.fda.gov/media/180206/download https://www.fda.gov/regulatory-information/search-fda-guidance-documents/postapproval-manufacturing-changes-biosimilar-and-interchangeable-biosimilar-products-questions-and